This meta-analysis was designed to update data on clinical outcomes with aspiration thrombectomy or mechanical thrombectomy before primary percutaneous coronary intervention (PCI) compared with conventional primary PCI alone.
Background
The clinical efficacy of thrombectomy in acute myocardial infarction (AMI) remains uncertain.
Methods
Clinical trials that randomized AMI patients to aspiration (18 trials, n ¼ 3,936) or mechanical thrombectomy (7 trials, n ¼ 1,598) before PCI compared with conventional PCI alone were included.
Results
The weighted mean duration of clinical follow-up was 6 months. Aspiration thrombectomy vs. conventional primary PCI (18 
Conclusions
Thrombectomy during AMI by manual catheter aspiration, but not mechanically, is beneficial in reducing MACE, including mortality, at 6 to 12 months compared with conventional primary PCI alone. To reduce distal embolization, a number of adjunctive devices have been studied for use with primary percutaneous intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). Broadly, they are classified as aspiration thrombectomy (e.g., Export catheter, Medtronic, Minneapolis, Minnesota), mechanical thrombectomy (e.g., AngioJet, Medrad Interventional/Possis, Minneapolis, Minnesota), and embolic protection devices (e.g., Percusurge GuardWire, Minneapolis, Minnesota). In an earlier meta-analysis, we had demonstrated a salutary effect of aspiration thrombectomy devices on myocardial reperfusion parameters and mortality, whereas mechanical thrombectomy devices appeared to be associated with an increased risk of mortality (1).
These findings were incorporated into the 2009 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the management of patients with STEMI, and aspiration thrombectomy currently carries a Class IIa recommendation for use with primary PCI (2) . However, the most recent trial on this topic showed no benefit on final infarct size at 30 days with routine aspiration thrombectomy in high-risk STEMI patients undergoing primary PCI (3) . Similarly, the JETSTENT (AngioJet Rheolytic Thrombectomy Before Direct Infarct Artery Stenting With Direct Stenting Alone in Patients With Acute Myocardial Infarction) trial (4) demonstrated a beneficial effect on major adverse cardiac events (MACE) with adjunctive mechanical thrombectomy over routine PCI in these patients. Because additional studies and prolonged follow-up of earlier trials have now been reported, we sought to perform an updated meta-analysis to determine the relative magnitude of benefit of adjunctive aspiration and mechanical thrombectomy devices on clinical and surrogate markers of reperfusion as compared with conventional primary PCI alone in patients presenting with STEMI.
Methods
Literature review. A computerized literature search of the Cochrane, Embase, and MEDLINE databases was conducted for randomized controlled trials published from January 1996 to December 2012, using the Medical Subject Heading and the key word search terms thrombectomy, thrombus aspiration, thromboaspiration, aspiration, mechanical, infarction, and myocardial infarction. Only English-language studies were included. We also obtained recently presented data at national and international cardiology conferences. We also corresponded with authors when final results were not available and reviewed other meta-analyses on this topic. Additionally, we used Internet-based sources of information (http://www.cardiosource.com, http://www.clinicaltrials.gov, http://www.theheart.org, and http://www.tctmd.com). Selection criteria. We selected studies that randomized patients within 12 h of acute myocardial infarction (AMI) to either: 1) aspiration thrombectomy and primary PCI versus primary PCI alone or 2) mechanical thrombectomy and primary PCI versus primary PCI alone. We only included studies that reported clinical outcomes data and/or markers of myocardial reperfusion. We excluded studies that performed thrombectomy on saphenous vein grafts or that compared one thrombectomy device to another. Outcomes/data abstraction. The primary clinical endpoint of interest was all-cause mortality. Secondary endpoints were recurrence of MI, target vessel revascularization, and MACE (composite of death, MI, and target vessel revascularization). Myocardial reperfusion was examined at 2 distinct time frames: immediately post-procedure (myocardial blush grade and ST-segment resolution) and at 1 to 3 months (change in infarct size and left ventricular ejection fraction after primary PCI). Definitions used to abstract outcomes are outlined in the Online Appendix. Outcomes were tabulated by 2 independent reviewers (D.J.K., A.A.B.) and the number of events that occurred among each arm of a trial recorded. Discrepancies were resolved through discussion, and a third reviewer (D.L.B.) when necessary. Statistical analysis. The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement was followed for this meta-analysis (5) . For all clinical outcomes, an intention-to-treat analysis was utilized. For the reperfusion and infarct size outcomes, treatment-received (or per-protocol) analysis was utilized because there were generally fewer patients available for the determination of these outcomes. Summary relative risks (RRs) and their corresponding 95% confidence intervals (CIs) were computed for each dichotomous outcome using fixed-and randomeffects (DerSimonian and Laird method) models (6) . For outcomes with significant heterogeneity, the random-effects model is reported in the text and figures; for all others, the fixed-effects models are reported. If a study had no events in 1 group, we added 0.5 to each cell of the 2 Â 2 table for that study to compute the summary RR. Heterogeneity between studies was assessed by calculating an I 2 statistic and publication bias with Begg's funnel plot method (7) . For infarct size, the weighted mean difference (WMD) and corresponding 95% CIs were computed using random-effects modeling (8) . Where these data were unavailable (4,9), they were imputed from available data using published approaches (10, 11) . Where significant heterogeneity was noted, the impact of important baseline covariates was examined using random-effects meta-regression, including baseline Thrombolysis In Myocardial Infarction (TIMI) flow grade 0/1, glycoprotein IIb/IIIa inhibitor use, direct stenting, and total ischemic time. As a form of sensitivity analysis, we repeated the aspiration thrombectomy versus conventional primary PCI analyses after exclusion of the TAPAS (Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study) (12) . A sensitivity analysis was also planned after removing studies of low methodologic quality based on bias assessment (13) . Because the experimental arm was an interventional device, concealment of allocation sequence was not possible. With the exception of a few studies (mostly abstracts) where it was unclear, outcome assessment was blinded in all trials. Thus, a sensitivity analysis based on quality was not pursued.
Mean follow-up was weighted according to the sample sizes of individual trials. All p values were 2-tailed, with statistical significance set at 0.05, and CIs were calculated at the 95% level. All analyses were performed using STATA software version 10.0 (STATA Corporation, College Station, Texas).
Results
A total of 25 trials in 5,534 patients met our selection criteria (3, 4, 9, 12, (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . Of these, 1,944 patients underwent adjunctive aspiration thrombectomy; 779, adjunctive mechanical thrombectomy; and 2,811, conventional primary PCI alone. The baseline characteristics of the included patients are listed in Table 1 . The mean ischemic time ranged from 2.4 to 7.6 h. TIMI flow grade 0/1 at baseline was noted in 63% to 100% of patients. All patients received aspirin before the procedure. Although the majority of patients received a thienopyridine pre-or post-procedure, this information was unavailable in 3 trials (26, 27, 33 Fig. 1 ). Meta-regression did not identify a difference based on baseline TIMI flow grade 0/1, glycoprotein IIb/IIIa inhibitor use, direct stenting, or total ischemic time for either of these outcomes.
FINAL INFARCT SIZE AND EJECTION FRACTION.
Information on final infarct size was available in 7 studies (n ¼ 950), and it was studied using delayed enhancement -cardiac magnetic resonance imaging (DE-CMR) in 4 studies (3, 20, 26, 33) and using technetium-99m sestamibi in the other 3 (9,23,24) ( Table 2 ). The mean duration of follow-up was 35.9 days (range: hospital discharge to 6 months). There was no difference in final infarct size between the aspiration thrombectomy and PCI-only arms (17.1% vs. 17.3%; WMD: -0.85%; 95% CI: -4.37% to 2.67%; p ¼ 0.64). On restricting the analysis to DE-CMR studies only, there was still no difference in final infarct size between the 2 arms (WMD: -1.92%, 95% CI: -5.04% to 1.20%; p ¼ 0.23). Information on final ejection fraction was available in 9 studies and was obtained using CMR in 4 studies (3, 20, 24, 33) , SPECT in 1 (9), echocardiography in 3 (18, 22, 25) , and cine-ventriculography in 1 (19) ( Table 2 ). There was no difference in final ejection fraction between the 2 arms (53.0% vs. 52.8%; WMD: 1.09%; 95% CI: -1.06% to 3.24%; p ¼ 0.32) (Online Fig. 2) . Further, no difference was noted on restricting the analysis to studies assessing ejection fraction beyond 1 month (n ¼ 6) (WMD: 2.32%; 95% CI: -0.89% to 5.53%; p ¼ 0.16). (Fig. 1) Fig. 3 ). Meta-regression did not identify a difference in outcomes based on baseline TIMI flow grade 0/1, glycoprotein IIb/IIIa inhibitor use, direct stenting, or total ischemic time for either of the 2 outcomes.
Data on final infarct size were available for 4 studies (n ¼ 1,043), and studied using DE-CMR in 1 study (33) and with technetium99m sestamibi in the other 3 (4,28,30) ( Table 2 ). The mean duration of follow-up was 33.2 days (range: 21 to 90 days). There was no difference in final infarct size between the mechanical thrombectomy and PCI-only arms (12.7% vs. 13.3%; WMD: -1.34%; 95% CI: -4.98 to 2.29; p ¼ 0.47) (Online Fig. 4) . Final ejection fraction could not be analyzed because data were available from 2 studies only.
CLINICAL OUTCOMES. The weighted mean duration of follow-up was 6.2 months (range: 1 to 12 months). The primary endpoint of all-cause mortality was similar between the mechanical thrombectomy and PCI-only arms (4.5% vs. 3.9%; RR: 1.20; 95% CI: 0.64 to 2.23; p ¼ 0.57). There was evidence of moderate heterogeneity (I 2 : 30%), but no evidence of publication bias (p ¼ 1.0). Meta-regression did not identify any difference in mortality based on baseline TIMI flow grade 0/1, glycoprotein IIb/IIIa inhibitor use, direct stenting, or total ischemic time. Reinfarction (0.8% vs. 1.4%; RR: 0.62; 95% CI: 0.23 to 1.62; p ¼ 0.32), target vessel revascularization (4.0% vs. 5.1%; RR: 0.74; 95% CI: 0.48 to 1.16; p ¼ 0.19), all strokes (1.3% vs. 0.4%; RR: 2.74; 95% CI: 0.93 to 8.01; p ¼ 0.07), and the composite MACE outcome (10.1% vs. 10.9%; RR: 1.10; 95% CI: 0.59 to 2.05; p ¼ 0.77) were all similar between the mechanical thrombectomy and PCI-only arms (Fig. 2) .
Discussion
Our meta-analysis of data from 5,534 patients with AMI in 25 trials indicates that as compared with conventional
primary PCI alone, aspiration thrombectomy was associated with a significant 24% reduction in MACE, including a 29% reduction in all-cause mortality at 6 months' median followup. Rates of reinfarction and target vessel revascularization were also numerically lower. On the other hand, mechanical thrombectomy had a neutral effect on clinical outcomes as compared with conventional primary PCI alone, with a consistent and concerning trend toward a higher incidence of stroke in all trials evaluated.
Given the importance of this topic and disparate results from the different clinical trials, a number of prior metaanalyses have been conducted (34) (35) (36) . However, they have been limited by their duration of follow-up (30 days) and by combining all available devices into one thrombectomy category. Our findings extend findings from these prior metaanalyses, in that although no benefit in clinical outcomes was noted with aspiration thrombectomy at 30 days, we report a benefit at 6 to 12 months of follow-up. Our immediate reperfusion results are also similar to the only published headto-head trial (n ¼ 99) between the 2 types of devices wherein aspiration thrombectomy resulted in superior reperfusion as compared with mechanical thrombectomy (37) .
In the context of aspiration thrombectomy, 2 trials deserve special mention. On one hand, the results of the recent INFUSE-AMI trial may have caused uncertainty in the minds of some cardiologists regarding the utility of adjunctive thrombectomy for primary PCI patients. The primary endpoint for the INFUSE-AMI trial was final infarct size on DE-CMR, and was similar at 30 days between the aspiration thrombectomy and conventional primary PCI arms alone. Our findings are reassuring in that despite the inclusion of INFUSE-AMI, there remains a continued mortality benefit with aspiration thrombectomy at 6 to 12 months over conventional primary PCI. On the other hand, the only trial to show a mortality benefit with aspiration thrombectomy was TAPAS. This trial has been criticized for numerous reasons. These include possible selection bias (single-center study), unclear mechanism (no difference in enzymatic infarct size post-procedure but a significant difference in cardiovascular and all-cause mortality at 1 year), and the possibility of chance (the trial was not originally powered for mortality) (12) . Our sensitivity analysis, however, suggests that even after exclusion of TAPAS from the analysis, there was still a significant reduction in MACEs at 6 months, driven predominantly by a reduction in target vessel revascularization rates. This could be due to better sizing of stents during the index procedure or less stent thrombosis as a result of thrombus removal (38) .
Along these lines, it is interesting that numerically lower target vessel revascularization rates at 6 to 12 months were noted with both aspiration and mechanical thrombectomy compared with conventional primary PCI. Could thrombus extraction and less target vessel revascularization/late stent thrombosis thus represent an alternative mechanism for long-term clinical benefit with aspiration thrombectomy despite no difference in infarct size at 1 month compared with conventional primary PCI? This finding is hypothesis generating and needs further study. In a recent study, the reference vessel diameter and minimal lumen diameter on dedicated quantitative angiographic analysis were both significantly greater with aspiration thrombectomy as compared with conventional primary PCI. Moreover, the mean stent area on optical frequency domain imaging was numerically larger with aspiration thrombectomy (39) . An interesting finding in our analysis is the discrepancy between infarct size and left ventricular ejection fraction at 1 month and clinical outcomes at 6 to 12 months. What might explain this disconnect? As far as infarct size is concerned, it is widely appreciated that SPECT imaging has lower spatial resolution than does DE-CMR, especially for subendocardial infarcts (40) . Thus, although SPECT studies were included to increase overall power, the addition of SPECT studies to DE-CMR studies to compare final infarct size estimates may have diluted the results. However, even after exclusion of the SPECT studies, we still noted that there was no difference in infarct size with aspiration thrombectomy. In the case of left ventricular ejection fraction, although there is good overall correlation between SPECT and CMR, discrepancies may be large for small changes (41) . Two-dimensional echocardiography and cine-ventriculography do not have the same October 15, 2013:1409-18 Adjunctive Thrombectomy for Primary PCI 1415 accuracy as CMR for ejection fraction determination (42, 43) . Also, as outlined in Table 2 , a significant proportion of patients clinically followed up in these trials did not have evaluable CMR studies (e.g., 22% in INFUSE-AMI and 59% in EXPIRA). This might have created selection bias and also a reduction in power to detect a true difference. From a technical standpoint, none of the DE-CMR studies reported image intensity thresholds utilized for infarct size quantification (44) . Significant interstudy variability may have resulted if different definitions were used by different trials (45) . Finally, surrogate endpoints do not always translate into clinically relevant outcomes, as has been noted several times before (46) .
Our findings argue against a routine role for mechanical thrombectomy in patients undergoing primary PCI. A higher risk of stroke with mechanical thrombectomy, as we previously reported (1), and further confirmed in this study is also concerning. However, it should be noted that the combined sample size of the mechanical thrombectomy trials was <50% that of the aspiration thrombectomy trials. It is possible that the inclusion of larger mechanical thrombectomy trials in the future may show a different result. Study limitations. Because this was a meta-analysis, the validity of our results is dependent on the validity of the studies included. We did not include patient-level data. We also included data that have been reported only in conference presentations or in abstract form and so have not undergone peer review. This inclusion was necessary to maximize the utilization of all available data on this important topic. The results of our sensitivity analysis suggest that results obtained by including data from abstracts did not differ significantly from results obtained from published manuscripts only (data not shown). We did not include other measures of infarct size, such as creatine kinase-myocardial band or troponin measurements, due to inconsistent reporting.
Two large multicenter trials comparing aspiration thrombectomy to conventional primary PCI, both powered for clinical endpoints, are currently ongoing (47, 48) . Until such time that these results are available, our current analysis supports the routine use of aspiration thrombectomy devices as adjunctive therapy in STEMI patients undergoing primary PCI over conventional primary PCI alone. The current IIa recommendation in the ACC/AHA STEMI guidelines also appears justified. Mechanical thrombectomy, on the other hand, does not appear to affect clinical outcomes and cannot be recommended for routine use in this patient population at this time.
Conclusions
Thrombectomy during AMI by manual catheter aspiration, but not mechanically, is beneficial in reducing MACE, including mortality, at 6 to 12 months compared with conventional PCI alone.
